New Monoclonal Antibody Showed Better Safety Profile
An investigational antibody for COVID-19 demonstrated improved safety over mRNA vaccines in a recent phase 3 trial.
Updated on Oct. 12, 2026 in COVID-19
Live Poll
Would you be more likely to get preventative antibody treatments if they were simple injections?
In the phase 3 LIBERTY trial, the investigational monoclonal antibody VYD2311 showed a superior safety and tolerability profile compared to an mRNA-based COVID-19 vaccine. This development could eventually offer a new prophylactic option for those needing immune support.
Why it matters
The shift to intramuscular delivery allows for administration in standard pharmacies or clinic settings, removing the requirement for specialized infusion centers. This change could increase access to preventive monoclonal antibody treatments.
The phase 3 LIBERTY trial evaluated the investigational antibody VYD2311, which utilizes the same backbone as the prophylactic pemivibart. Findings published on October 1, 2026, show a tenfold increase in potency compared to earlier versions, enabling a 250 mg intramuscular injection.
The players
Invivyd
A biotechnology company focused on developing antibody-based therapies for the prevention and treatment of infectious diseases like COVID-19.
The details
Researchers created VYD2311 by modifying a few amino acids within the existing pemivibart antibody backbone. This structural change increased the antibody's potency by approximately tenfold, which is the mechanism that enables the shift from a large 4500 mg intravenous infusion to a 250 mg intramuscular injection. Invivyd is also investigating the potential for subcutaneous injections to further simplify administration for home use.
Timeline
October 1, 2026: Study results reporting the safety profile were published.
Health Landscape
The LIBERTY trial (NCT07655180) represents a significant shift in antibody delivery methods, moving away from high-dose intravenous infusion models. This development updates the therapeutic landscape by demonstrating that antibody engineering can transition prophylaxis to accessible intramuscular injections.
This research suggests a future where preventive monoclonal antibodies may be more accessible through local clinics rather than specialized infusion sites. If you require specialized immune support, discuss current prophylactic options and upcoming clinical developments with your physician.
The takeaway
The development of VYD2311 highlights how molecular engineering can increase treatment potency while improving the patient experience through simpler administration. Monitor updates from your healthcare provider regarding new preventive options for vulnerable populations as research continues.
Further reading
Learn more about the latest COVID-19 research and preventive strategies on our dedicated topic page.
Source note: This article includes information reported by Ajmc.
Live Poll
Would you be more likely to get preventative antibody treatments if they were simple injections?
